LEASE AGREEMENTLease Agreement • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
THIS LEASE AGREEMENT is made as of this 22 day of August, 2012, between ARE-TECH SQUARE, LLC, a Delaware limited liability company (“Landlord”), and WARP DRIVE BIO, LLC, a Delaware limited liability company (“Tenant”).
SUBLEASESublease • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of January 16, 2019, and is made by and between ONCOMED PHARMACEUTICALS, INC., a Delaware corporation (“Sublandlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Subtenant”). Sublandlord and Subtenant hereby agree as follows:
REVOLUTION MEDICINES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 5, 2019Investors’ Rights Agreement • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of June, 2019, by and among REVOLUTION MEDICINES, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof (collectively, “Investors”), and amends and restates that certain Investors’ Rights Agreement, dated as of March 23, 2018, by and among the Company and the investors listed on Schedule A thereto, as amended (the “Prior Agreement”).
ASSIGNMENT AND ASSUMPTION OF LEASEAssignment and Assumption of Lease • October 31st, 2019 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS ASSIGNMENT AND ASSUMPTION OF LEASE (this “Assignment”) is made by and between WARP DRIVE BIO, LLC, a Delaware limited liability company (“Assignor”) and REVOLUTION MEDICINES, INC., a Delaware corporation (“Assignee”) as of January 30, 2019 (the “Effective Date”).
